AG˹ٷ

STOCK TITAN

Prime Medicine Announces Proposed Public Offering of Common Stock

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags

Prime Medicine (Nasdaq: PRME), a biotechnology company focused on curative genetic therapies, has announced a proposed public offering of common stock. The company will grant underwriters a 30-day option to purchase an additional 15% of the offered shares.

The offering will be managed by TD Cowen and BMO Capital Markets as joint book-running managers. The shares will be offered through a previously filed shelf registration statement that became effective on November 13, 2023. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Prime Medicine (Nasdaq: PRME), un'azienda biotecnologica specializzata in terapie genetiche curative, ha annunciato una proposta di offerta pubblica di azioni ordinarie. La società concederà agli underwriter un opzione di 30 giorni per l'acquisto di un ulteriore 15% delle azioni offerte.

L'offerta sarà gestita congiuntamente da TD Cowen e BMO Capital Markets come joint book-running manager. Le azioni saranno offerte tramite una dichiarazione di registrazione a scaffale precedentemente depositata, diventata efficace il 13 novembre 2023. I termini definitivi dell'offerta saranno resi noti in un supplemento finale al prospetto che sarà depositato presso la SEC.

Prime Medicine (Nasdaq: PRME), una compañía biotecnológica centrada en terapias genéticas curativas, ha anunciado una propuesta de oferta pública de acciones comunes. La empresa otorgará a los suscriptores una opción de 30 días para comprar un 15% adicional de las acciones ofrecidas.

La oferta será gestionada por TD Cowen y BMO Capital Markets como gestores conjuntos principales. Las acciones se ofrecerán a través de una declaración de registro en estantería previamente presentada que entró en vigor el 13 de noviembre de 2023. Los términos finales de la oferta se revelarán en un suplemento final del prospecto que se presentará ante la SEC.

Prime Medicine (나스�: PRME)� 치료� 유전� 치료제에 주력하는 생명공학 회사로서, 보통� 공개매출� 제안했다� 발표했습니다. 회사� 인수인에� 제공 주식� 추가 15%� 30일간 매수� � 있는 옵션� 부여할 예정입니�.

이번 공모� TD Cowen� BMO Capital Markets가 공동 주관사로 관리합니다. 주식은 2023� 11� 13�� 효력� 발생� 선행 등록서류� 통해 제공됩니�. 공모� 최종 조건은 SEC� 제출� 최종 안내� 보충자료� 공개� 예정입니�.

Prime Medicine (Nasdaq : PRME), une entreprise biotechnologique spécialisée dans les thérapies génétiques curatives, a annoncé une proposition d'offre publique d'actions ordinaires. La société accordera aux souscripteurs une option de 30 jours pour acheter 15 % supplémentaires des actions proposées.

L'offre sera gérée conjointement par TD Cowen et BMO Capital Markets en tant que chefs de file. Les actions seront proposées dans le cadre d'une déclaration d'enregistrement sur étagère déposée précédemment et entrée en vigueur le 13 novembre 2023. Les termes définitifs de l'offre seront divulgués dans un supplément final au prospectus qui sera déposé auprès de la SEC.

Prime Medicine (Nasdaq: PRME), ein Biotechnologieunternehmen, das sich auf heilende Gentherapien spezialisiert hat, hat ein geplantes öffentliches Angebot von Stammaktien angekündigt. Das Unternehmen wird den Underwritern eine 30-tägige Option zum Kauf von zusätzlichen 15% der angebotenen Aktien gewähren.

Das Angebot wird von TD Cowen und BMO Capital Markets als gemeinsame Bookrunner verwaltet. Die Aktien werden über eine zuvor eingereichte Shelf-Registrierung angeboten, die am 13. November 2023 wirksam wurde. Die endgültigen Bedingungen des Angebots werden in einem endgültigen Prospektergänzungsdokument veröffentlicht, das bei der SEC eingereicht wird.

Positive
  • Additional capital raised can fund research and development activities
  • Strengthens balance sheet for future operations
Negative
  • Potential dilution for existing shareholders
  • Stock price may face downward pressure due to increased share supply

Insights

Prime Medicine is raising capital through a stock offering, likely diluting current shareholders while securing funds for their gene therapy pipeline.

Prime Medicine has announced plans for a public offering of common stock, a move that typically signals the company's need for additional capital to fund operations and research. As a clinical-stage biotechnology company focused on genetic therapies, Prime Medicine operates in a capital-intensive sector where companies frequently require substantial funding before generating revenue.

The offering includes a 30-day option for underwriters (TD Cowen and BMO Capital Markets) to purchase an additional 15% of the offered shares. This structure is standard for biotech offerings, providing flexibility to capture additional capital if demand proves strong.

For current shareholders, this offering will likely result in dilution of their ownership percentage once the new shares are issued. The degree of dilution depends on the final size of the offering, which hasn't been disclosed in this announcement.

The timing of this capital raise is noteworthy. Biotechnology companies typically initiate public offerings when they need to extend their operational runway or fund specific clinical programs. For Prime Medicine, with its focus on "one-time curative genetic therapies," this capital will likely support their clinical development pipeline.

The company is using a shelf registration statement that was filed in November 2023, which streamlines the offering process. The absence of specific pricing information indicates this is the initial announcement, with final terms to be disclosed in subsequent filings.

CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that it has commenced an underwritten public offering of shares of its common stock. Prime Medicine also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of its common stock offered in the public offering. All of the shares of common stock in the proposed offering are to be sold by Prime Medicine. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

TD Cowen and BMO Capital Markets are acting as joint book-running managers for the proposed offering.

The shares of common stock are being offered by Prime Medicine pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at

When available, copies of the preliminary prospectus supplement relating to the offering may also be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at [email protected]; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at

The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine’s beliefs and expectations regarding: the timing, terms and size of the proposed public offering, and the possibility that the proposed offering will be completed on the anticipated terms or at all. The words “may,� “might,� “will,� “could,� “would,� “should,� “expect,� “plan,� “anticipate,� “intend,� “believe,� “expect,� “estimate,� “seek,� “predict,� “future,� “project,� “potential,� “continue,� “target� and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward­ looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed offering. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors� in Prime Medicine’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and any of its subsequent filings with the SEC. In addition, any forward-looking statements represent Prime Medicine’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor and Media Contacts

Gregory Dearborn
Prime Medicine
857-209-0696
[email protected]

Hannah Deresiewicz
Precision AQ
212-362-1200
[email protected]


FAQ

What is the purpose of Prime Medicine's (PRME) public stock offering in July 2025?

Prime Medicine is conducting a public offering of common stock to raise additional capital, with TD Cowen and BMO Capital Markets acting as joint book-running managers.

How many additional shares can underwriters purchase in PRME's offering?

Underwriters will have a 30-day option to purchase up to an additional 15% of the shares offered in the public offering.

When did Prime Medicine's shelf registration statement become effective?

Prime Medicine's shelf registration statement became effective on November 13, 2023 (File No. 333-275321).

Who are the book-running managers for Prime Medicine's 2025 stock offering?

TD Cowen and BMO Capital Markets are acting as joint book-running managers for the proposed offering.

What is the expected impact of PRME's stock offering on existing shareholders?

The stock offering may lead to dilution of existing shareholders' ownership and potential downward pressure on the stock price due to increased share supply.
Prime Medicine

NASDAQ:PRME

PRME Rankings

PRME Latest News

PRME Latest SEC Filings

PRME Stock Data

550.09M
102.56M
23.91%
59.05%
13.76%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE